These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 15815728)
1. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Holtz MS; Forman SJ; Bhatia R Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728 [TBL] [Abstract][Full Text] [Related]
3. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346 [TBL] [Abstract][Full Text] [Related]
4. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Holtz M; Forman SJ; Bhatia R Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145 [TBL] [Abstract][Full Text] [Related]
5. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Chu S; Holtz M; Gupta M; Bhatia R Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699 [TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Holtz MS; Slovak ML; Zhang F; Sawyers CL; Forman SJ; Bhatia R Blood; 2002 May; 99(10):3792-800. PubMed ID: 11986238 [TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
9. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells. Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144 [TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101 [TBL] [Abstract][Full Text] [Related]
11. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells. Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776 [TBL] [Abstract][Full Text] [Related]
12. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases. Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829 [TBL] [Abstract][Full Text] [Related]
13. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631 [TBL] [Abstract][Full Text] [Related]
14. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
15. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844 [TBL] [Abstract][Full Text] [Related]
17. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG. Radujkovic A; Schad M; Topaly J; Veldwijk MR; Laufs S; Schultheis BS; Jauch A; Melo JV; Fruehauf S; Zeller WJ Leukemia; 2005 Jul; 19(7):1198-206. PubMed ID: 15902298 [TBL] [Abstract][Full Text] [Related]
18. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334 [TBL] [Abstract][Full Text] [Related]
19. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Rahmani M; Nguyen TK; Dent P; Grant S Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328 [TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]